• Cart


Suresh Vedantham, MDSuresh Vedantham, MD
National Principal Investigator

In 2026, progress has been made in pulmonary embolism (PE) management enabled by local multispecialty collaboration, new multisociety guidelines that provide robust guidance on patient selection for advanced PE interventions, and completed or nearly completed industry-sponsored trials evaluating catheter-directed PE therapies (STORM-PE, HI-PEITHO, PEERLESS-2).1-3 And on June 21, 2026, the investigators of the NIH-sponsored, multicenter, randomized PE-TRACT (Pulmonary Embolism – Thrombus Removal with Adjunctive Catheter-Directed Therapy) trial achieved an impressive collaborative feat in completing enrollment of the trial’s full 500-patient sample a year ahead of schedule.4

PE-TRACT is distinct from other trials. First, funded only by NHLBI and featuring rigorous methodology, PE-TRACT will be highly credible as a source of unbiased information on CDT outcomes. Second, PE-TRACT is unique in focusing on 3- to 12-month functional outcomes: its dual primary outcome structure includes the 3-month peak oxygen uptake (PVO2) on cardiopulmonary exercise testing (CPET) and the 12-month New York Heart Association class. This scheme will enable assessment of whether CDT indeed prevents “post-PE syndrome,” a key gap in knowledge not elsewhere addressed. Third, reflecting its long-term assessment goal, PE-TRACT enrolled a cohort that encompasses a broad spectrum of patients with intermediate-risk PE, in contrast to studies that enriched their populations for higher clinical severity. By capturing clinical outcome, physiological outcome, and blood specimens, PE-TRACT was designed to enable new insights into the biology of PE, patient recovery, and the development of post-PE syndrome. We look forward to sharing results in late 2027.

Even better, the NIH has recognized the success of the PE-TRACT network and is doubling down! On August 6, 2026, we received the incredible news that the NHLBI is funding the $4 million PE-TRACT EXTEND ancillary study, led by Drs. Akhilesh Sista and Timothy Morris. In EXTEND, participants in the main PE-TRACT trial will have extended clinical follow-up to: (a) develop detailed biological profiles of the different phenotypes of symptomatic chronic thromboembolism; (b) explore the role of CDT in defining post-PE course; and (c) determine the interplay between biological processes, embolic burden, and clinical variables via multivariate analysis of functional genomic data and advanced blood specimen testing. A long-term goal is to enable phenotype-specific therapy via identification of biomarkers and new molecular targets.

So, we have come full circle – what started as a study focused on an intervention is growing into a long-term program to understand post-PE disease processes. Just the way science is supposed to work!

Acknowledgments

The PE-TRACT trial’s development was previously supported by NHLBI grants U34-HL147347 and UG3-HL155798 (to Dr Akhilesh Sista at New York University) and is currently supported by NHLBI grants UH3-HL155798 (to Drs Sunil Rao at New York University and Suresh Vedantham at Washington University in St. Louis) and U24-HL155811 (to Dr Andrea Troxel at New York University). The content in this article is solely the responsibility of the author, not the NHLBI or NIH. The author thanks the NHLBI; the PE-TRACT Trial Steering Committee, site investigators, and staff; and the patients who volunteered to participate.

References:

  1. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026; 153(12):e977-e1051. Erratum in: Circulation. 2026 Jul 14;154(2):e24.
  2. Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: primary outcomes from the STORM-PE Trial. Circulation 2026; 153(1):21-34.
  3. Rosenfield K, Klok FA, Piazza G, et al. Ultrasound-facilitated, catheter-directed fibrinolysis for acute pulmonary embolism. N Engl J Med 2026; 394(20):1979-1990.
  4. Sista AK, Troxel AB, Tarpey T, et al. Rationale and design of the PE-TRACT trial: a multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism. Am Heart J 2025; 281:112–122.
AVF 2027 - Harmony in Venous Care February 27 - March 2 Grand Hyatt Nashville